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Abstract 
Oral Thin Film (OTF) is a newly emerging drug delivery system which has 
many benefits for patients. Although there has been some formulation of OTF 
products, these have mainly been as confectionary or dental health products. 
The most significant benefit of this dosage format will only be realised once 
more pharmaceutical products become available. Within this paper, OTF 
strips containing Diclofenac Sodium were prepared using the solvent casting 
method and then characterised to ensure the method could conform to 
acceptable levels of uniformity, the mean (SD) diclofenac sodium content was 
25.43(1.39) mg, range 22.84-27.44 mg. Bioburden was tested against 
coliforms, yeasts and moulds and all results were confirmed to be <10 CFU/g, 
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also similar dissolution profile when compared to a commercial product to 
ensure biowaiver. An acceptable level of uniformity of mass was produced. K-
F titration was employed to reduce the water content of the strips and it was 
found to be acceptable, this represented a level of water which would not be 
viable for microbial growth. The technique employed here in the production of 
OTF resulted in high quality products and amenability to being up scaled. 
Furthermore, the characterisation method was also sufficient to assess the 
quality of the products and may be used for future analysis of OTF 
pharmaceuticals. 
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1. Introduction 
Diclofenac is one of the most commonly prescribed non-steroidal anti-
inflammatory drugs (NSAIDs), used in the treatment of pain and inflammatory 
conditions since its introduction in 1970s. Like all NSAIDs, diclofenac exerts 
its effects through the inhibition of prostaglandin synthesis by blocking 
cyclooxygenase enzymes COX-1 and COX-2. It is available in two salt forms: 
diclofenac sodium and diclofenac potassium, with the sodium salt being the 
most commonly prescribed [1]. Indications for its use include rheumatic 
disease, gout, migraine, musculoskeletal and post-operative pain. It is also 
used topically in actinic keratosis, ophthalmically for peri- and post-operative 
inflammation and seasonal allergic conjunctivitis, and has been associated 
with an opioid-sparing effects in cancer pain therapy [2-4]. Diclofenac is very 
well absorbed via the oral route, undergoes extensive first-pass metabolism, 
binds almost entirely to plasma proteins at therapeutic levels and has a half-
life of approximately 1-2 hours [5]. 
 
Orodispersible thin films (OTFs) were first established as breath fresheners 
and have since progressed to the delivery of active pharmaceutical 
ingredients (APIs). Composed principally of one or more water soluble, film-
forming polymers, OTFs dissolve very rapidly in contact with saliva, releasing 
the active ingredient(s) without the need to chew or drink water [6]. This 
makes them ideally suited to elderly or paediatric populations, who may have 
difficulty swallowing other solid oral dosage forms such as tablets or capsules. 
OTFs are thin films typically the size of a postage stamp and can be 
formulated using minimal food or pharmaceutical grade excipients. They are 
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discreet, convenient and easy to take. Typically, alongside the film-forming 
polymer(s), an OTF formulation will include a plasticizer e.g. glycerol, to give 
the film strength and flexibility [7]. Flavour and sweetener combinations can 
also be included to help mask bitter tasting drugs [8, 9]. Commonly used film-
forming polymers include cellulose-based polymers such hydroxypropyl 
methylcellulose, pullulan, starches and maltodextrins [10]. In 2010, Zuplenz® 
became the first FDA approved prescription only medicine in an OTF 
formulation for the delivery of ondansetron in the treatment of postoperative 
chemotherapy- and radiotherapy-induced nausea and vomiting [11]. More 
recently in February 2012, Applied Pharma Research were successful in 
marketing a prescription only zolmitriptan based OTF product for the 
treatment of migraine [12]. 
 
Many APIs have an unpleasant, bitter taste. This can result in non-compliance 
with drug regimens where the formulation is unacceptable to the patient; this 
is especially true in the case of paediatrics. Taste masking of pharmaceutical 
actives may be achieved through a variety of methods and technologies, from 
addition of simple flavour and sweetener combinations through to more 
complex systems such as drug complexation with ion exchange resins or 
cyclodextrins [13-15]. 
 
To overcome the above mentioned problems and to increase the compliance 
of diclofenac sodium preperaions, the primary aim of this project was to 
formulate a rapidly dissolving, immediate release thin film which contained 25 
mg of diclofenac sodium for oral delivery. The film should be flexible and non-
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brittle with suitable mechanical properties to resist handling. The film should 
also have acceptable organoleptic properties – taste, aroma, mouth feel – 
with effective taste masking of the bitter active pharmaceutical ingredient. 
 
2. Materials and methods 
2.1. Oral thin film preparation 
Diclofenac sodium (Amoli Organics Pvt. Ltd., India), glycerol (Sigma Aldrich, 
UK), spearmint mild flavour (Givaudan, Switzerland), citric acid (Sigma 
Aldrich, UK), polyethylene glycol 1500 (Fluka, Germany), sucralose (Tate & 
Lyle, UK) and water were weighed and mixed using an Ultra-Turrax® T50 
basic S2 homogeniser (IKA-Werke GMBH & Co., Germany; Serial No. D-
79219). Hydroxypropyl methylcellulose E3 (Colorcon, UK) was added 
gradually to the mixture under continuous mixing until a homogenous, viscous 
solution formed, Table 1 listed quantities required. The solution was then 
degased under vacuum. The viscous solution was cast onto polymer coated 
paper using an Automatic Film Applicator (Sheen Instruments Ltd., Kingston, 
UK; Serial No. 5254290) with a Micrometer Adjustable Film Applicator 
1117/250 mm (Sheen Instruments Ltd., Kingston, UK; Serial No. 094606/50) 
that been adjusted to give the right thickness of the film and dried at 40°C. 
Oral thin films were cut into the correct strip weight (110 mg) using a rotary 
blade. 
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Table 1. Ingredients used for the preparation of Diclofenac Sodium Oral thin film 
Material Target Weight (g) 
Diclofenac Sodium 12.80 
Glycerol 1.00 
Citric Acid 3.50 
PEG 1500 2.80 
Sucralose 2.80 
Spearmint Mild flavour 2.80 
Distilled Water 100.00 
HPMC E3 26.00 
 
2.2. HPLC method 
An isocratic high performance liquid chromatography method (HPLC) was 
optimized with a view to develop an assay method for diclofenac sodium. A 
Dionex HPLC system with Dionex autosampler ASI-100 was used for batch 
analyses which was coupled to a UV detector. A Spheroclone ODS 150 x 4.6 
mm x 5 μm C18 column was employed. A mobile phase consisting of 
methanol (Rathburns, Blackburn, UK) and water (80:20) adjusted to pH 4.0 
using glacial acetic acid with a flow rate of 1 mL/min at 280 nm wavelength 
was found to produce an acceptable retention time, plates and good 
resolution for diclofenac sodium. Calibration standards in the 0.1-0.5 mg/mL 
range were prepared from a 0.5 mg/mL diclofenac sodium stock solution, 
prepared in mobile phase. The stock solution was stored at 4°C protected 
from light. 
 
Linearity was assessed across a concentration range representing 40-200% 
of the anticipated test sample concentration. Between day variability was 
  
8 
 
established to determine intermediate precision. Five concentrations were 
measured on two consecutive days; three repeat measurements were 
performed at each concentration. 
 
2.3. Content, mass uniformity and cleaning verifiction 
The uniformity of content was assessed by high performance liquid 
chromatography (HPLC). Calibration standards of diclofenac sodium 0.5, 0.4, 
0.3, 0.2 and 0.1 mg/mL in mobile phase were prepared and run on the HPLC. 
The peak area was calculated for each standard solution and results plotted 
against concentration to yield a calibration curve for determination of sample 
batches. 20 randomly selected strips were individually weighed and dissolved 
in mobile phase, and assayed using HPLC. 
 
2.4. Dissolution 
Dissolution testing was carried out according to compendial paddle 
methodology [16]. Phosphate buffer (pH 6.8, 900 mL) was used as the 
dissolution media to represent intestinal pH. The USP paddle apparatus 
(COPLEY DIS 6000, Serial: 15302) was used with a paddle speed of 50 rpm 
at 37°C ± 0.5°C using the specified dissolution media and solutions were 
analysed using spectrophotometry at 280 nm (PG Instrument, T70+ UV/VIS 
Spectrometer). Measurements were taken every 5 minutes until completion 
and the average percentage drug release (n = 6) was plotted against time. 
Voltaren® 50 mg orodispersible tablets (Novartis, Germany) were used as a 
commercially available comparator product and dissolution was carried out by 
the same method.  
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2.5. Microbial bioburden 
Oral thin film samples were sent to ALcontrol Laboratories (Bellshill, UK) for 
microorganism testing. Samples were tested for aerobic colony count, 
coliforms, yeasts and moulds as per ISO 11737-1 which is used to determine 
a population of microorganism within products. 
 
2.6. Karl Fischer titration (water content) 
Karl Fisher titration analysis was performed using a DL37 coulometric titrator 
(Mettler Toledo, Leicester, UK) with Coulomat CG and A reagents (Sigma 
Aldrich, Poole, UK). The titrimeter accuracy was checked using Hydranal 1.00 
and 10.0 water standards (Sigma Aldrich). The solvents used were HPLC 
grade methanol (Rathburns, Blackburn, UK) and anhydrous DMSO (Sigma 
Aldrich, UK). Karl Fisher analysis of the oral strips were performed by adding 
a single strip to approximately 5 ml of solvent (methanol or DMSO). DMSO 
solubilized/suspended the strips over a few minutes, whereas with methanol 
the strips remained intact. Samples being analysed in methanol were left 
overnight before analysis. Water content determination was performed in 
triplicate and corrected for solvent water content. 
 
2.7. Organoleptic evaluation 
Taste acceptability was measured by a taste panel (single blinded) consisting 
of human volunteers (n = 6) using diclofenac sodium 25 mg oral thin films 
compared with a blank film (flavour only). The volunteers were asked to allow 
the oral thin films to disperse in their mouths and to record the palatability of 
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individual formulations after X seconds before removing the residue of the 
dosage form from their mouths without ingesting.  The volunteers then rinsed 
any formulation residue from their mouths by gargling with distilled water 
before evaluating another sample. The bitterness level was recorded on taste 
evaluation sheets. A four point scale was used to indicate acceptability: 1 star 
= very bitter, 2 stars = moderate to bitter, 3 stars = slightly bitter, and 4 stars = 
tasteless/taste masked. 
 
3. Results 
3.1. HPLC method validation 
A good linear relationship was found when the peak area of diclofenac sodium 
was plotted against the diclofenac sodium standard concentrations (R2 = 
0.9916). Results of between day variability are presented in Table 2. 
Table 2. Intermediate precision. Between day variability in peak area. 
Diclofenac sodium  
concentration 
(mg/mL) 
Day 1 Day 2 
Mean AUC 
(mAU*min) 
RSD 
(%) 
Mean AUC 
(mAU*min) 
RSD 
(%) 
0.5 158.49 0.55 151.08 0.57 
0.4 130.75 0.02 125.87 1.18 
0.3 98.85 0.19 93.81 1.12 
0.2 65.73 1.10 64.91 2.63 
0.1 33.30 3.03 30.93 1.33 
R-sq 0.999 0.9978 
 
3.2. Uniformity of content and mass 
The mean (SD) weight of the oral thin films dosage units (n = 20) was 
110.95(5.86) mg, range 100-121 mg. The mean (SD) diclofenac sodium 
content was 25.43(1.39) mg, range 22.84-27.44 mg. Although no 
specifications exist with respect to oral thin films, all dosage units conformed 
to pharmacopoeial requirements for immediate release tablet preparations 
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since no dosage unit deviated from the stated content (25 mg) by more than 
10%. In addition, no individual dosage unit exceeded the mean strip weight by 
more than 10%, therefore the batch also conformed to standards of mass 
uniformity. 
 
3.3. Cleaning verification 
Swabs of the work surface and balance used for weighing the ingredients 
were subject to the HPLC analysis as per section 2.3 after cleaning with soap 
and water, all the results were below the lower limit of quantification. 
 
3.4. In vitro dissolution profiling 
The results of the in vitro dissolution testing in phosphate buffer (pH 6.8, 900 
mL), to represent intestinal pH, over time were shown in figure 1. This 
represent the  average percentage drug release (n = 6) against time. The 
results were compared with the release profile of the commercially available 
comparator product (Voltaren® 50 mg orodispersible tablets) using the same 
dissolution conditions.  
  
12 
 
 
Figure 1. Drug release profiles of oral thin films vs. commercial comparator at pH 6.8. 
3.5. Karl Fischer titration (water content) 
The mean (SD) percentage water content for the oral thin films in methanol 
and hygroscopic DMSO were 11.9(0.4) and 15.2(0.9) percent respectively. 
The result obtained from the DMSO was higher than that of methanol. With 
methanol the strip did not dissolve (intact) and therefore only the free water 
was measured, whilst using DMSO the strips were completely dissolved, and 
therefore both the free and bound water could be measured.  
 
3.6. Microbial bioburden 
Samples were tested for aerobic colony count, coliforms, yeasts and moulds 
and all results were confirmed to be <10 CFU/g. The batch therefore 
conformed to the pharmacopoeial acceptance criteria for microbiological 
quality of non-sterile dosage forms i.e. total aerobic microbial count <103 
CFU/g and total yeast and mould count <102 CFU/g [17].  
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3.7. Organoleptic testing 
Results of the in vivo taste evaluation found the diclofenac sodium 
orodispersible thin films dissolved completely in the mouth in an average of 60 
seconds compared to the blank film, which dissolved in around 15 seconds. 
The volunteers rated the drug containing films 3 stars on average compared 
to 4 stars with the placebo film. This indicated that only a slight bitterness 
remained and a reasonable masking of the active ingredient was achieved. 
 
 
 
4. Discussion 
Drug delivery by an oral thin film (OTF) is a new formulation that is currently 
under development for use in general clinical practice. An oral thin film is 
made from hydrophilic polymers that rapidly dissolve in the oral cavity. OTFs 
have been examined since the 1970’s when the anaesthetic lidocaine was 
used for dental applications using a polymer film [18]. More recently in 2001, 
Pfizer’s Warner-Lambert consumer healthcare division launched a breath 
freshener using OTF technology – Listerine ® PocketPaksTM [19]. The films 
produced a “minty” flavour in the mouth by rapidly dissolving the on the 
tongue. Utilisation of OTF technology will provide a fast and effective 
mechanism for drug delivery. Absorption from the oral mucosa will be rapid 
and will avoid degradation by the acidic pH and digestive enzymes of the 
gastro-intestinal tract. The drug will also bypass first pass metabolism by the 
liver allowing for the administration of lower doses that still produce high 
efficacy therefore reducing the risk of side effects [20]. Moreover, ease of 
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administration suggests that OTFs are more likely to be tolerated by patients 
providing that they be of an acceptable taste.   
Therfore, in this study, a rapidly dissolving oral thin films containing 25 mg 
diclofenac sodium was successfully formulated and a taste mask of diclofenac 
sodium was achieved using a simple mixed sweetener and flavour strategy. 
The film possessed good mechanical properties, sufficient to resist handling, 
being flexible and non-brittle. Rapid drug release was achieved with complete 
release (>80%) within 15 minutes. Furthermore, a rapid and sensitive reverse 
phase HPLC method with UV detection was successfully used for the 
determination of diclofenac sodium in an oral thin film. The batch of oral thin 
films conformed to Pharmacopoeial standards of uniformity in terms of drug 
content and mass. Acceptable results were also achieved with respect to 
tensile strength, water content and micro-organism testing. The results of the 
Karl-Fischer titration and microbial bioburden testing supported the 
expectation that the preservative-free formulation would possess minimal 
available water to support significant microbial growth this comply with the 
Biofilm limited UK aaceptable standard criteria of less than 20% of water 
content . Orodispersible thin films are ideal for patients with swallowing 
difficulties as they dissolve very rapidly on the tongue in saliva, without the 
need to chew or drink water. This gives them advantage over other solid 
dosage designs such as tablets or capsules. Oral thin films are particularly 
suited to paediatric populations who may find swallowing other solid oral 
dosage forms difficult. Our diclofenac orodispersible film dissolved within 60 
seconds on contact with saliva which is comparable to commercial 
orodispersible tablet products [21, 22]. Although a sparse Pharmacopoeial 
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monograph for orodispersible thin films exists under oromucosal products, no 
specifics are given as to how quickly the formulation should disintegrate [23]. 
However, the British Pharmacopoeial states that for orodispersible tablet 
disintegration, units must disintegrate within 3 minutes, and our formulation 
complies with this requirement. 
 
5. Conclusion 
Here, we have succusfuly formulated an oral thin films fo diclofenac sodium 
which dissolved rapidly with excellent taste masking of diclofenac sodium. 
The film was strong enough to withstand any mechanical handling. This 
formulated OTF was able to achieve rapid release of diclofenac sodium within 
15 minuts after administration. This OTFs are ideal for patients with 
swallowing difficulties such as elderly and pediatric patients. 
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